| 摘要 |
<p>The present invention relates to a method of preventing or treating the neurogenic inflammation associated with the use of viral vectors in gene therapy in a mammal, including a human, by administering to the mammal an NK-1 receptor antagonist (e.g., a substance P receptor antagonist).</p> |
